



**ASAM** American Society of  
Addiction Medicine

#### OFFICERS

President  
Paul H. Earley, MD, DFASAM  
President-Elect  
William F. Haning, III, MD, DFAPA, DFASAM  
Vice President  
Yngvild K. Olsen, MD, MPH, DFASAM  
Secretary  
Jeffrey Selzer, MD, DFASAM  
Treasurer  
Kenneth I. Freedman, MD, MS, MBA, FACP, DFASAM  
Immediate Past President  
Kelly J. Clark, MD, MBA, DFAPA, DFASAM

#### BOARD OF DIRECTORS

Directors-at-Large  
Anthony Albanese, MD, DFASAM  
Adam J. Gordon, MD, MPH, FACP, DFASAM  
Brian Hurley, MD, MBA, DFASAM  
Margaret Jarvis, MD, DFASAM  
Marla D. Kushner, DO, FSAHM, FACOFP, DFASAM  
Timothy Wiegand, MD, FACMT, FAACT, DFASAM

#### REGIONAL DIRECTORS

Anika, Alvanzo, MD, MS, FACP, DFASAM  
Gavin Bart, MD, PhD, DFASAM  
Gregory X. Boehm, MD, DFASAM  
Murtuza Ghadiali, MD, FASAM  
Frank James, MD, JD, FASAM  
Miriam Komaromy, MD, FACP, DFASAM  
A. Kenison Roy, III, MD, DLFAPA, DFASAM  
Peter Selby, MBBS, CCFP, FCFP, MHSc, DFASAM  
Scott Teitelbaum, MD, DFASAM  
Melissa Weimer, DO, MCR, FASAM

#### EX-OFFICIO

Brent Boyett, DO, DMD, DFASAM  
Joseph M. Garbely, DO, DFASAM  
Randolph P. Holmes, MD, FASAM  
Ilse Levin, DO  
Penny S. Mills, MBA, Executive Vice President/CEO  
Aleksandra Zgierska, MD, PhD, DFASAM

#### FOUNDING PRESIDENT

Ruth Fox, MD  
1895-1989

January 4, 2021

Timothy J. Shea  
Acting Administrator  
Drug Enforcement Administration  
Department of Justice  
8701 Morrissette Drive, Springfield, VA 22152

Re: Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment

Dear Mr. Shea:

On behalf of the American Society of Addiction Medicine (ASAM), a national medical specialty society representing more than 6,600 physicians and associated health professionals who specialize in the prevention and treatment of addiction, thank you for the opportunity to provide comments on the Interim Final Rule on the Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities (SUPPORT) Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment (the "Interim Final Rule").

The Interim Final Rule implements, among other policies, Sec. 3204 of the SUPPORT Act, which amends the Controlled Substances Act to set forth the conditions under which a pharmacy may deliver a controlled substance to an administering practitioner. The intent of this section was to expand access to long acting injectable/implantable ("LAI") buprenorphine products by creating an alternative to the "buy and bill" delivery system for these products. With that intent in mind, and knowing that the Government Accountability Office's August 2020 Report on Treatment with Injectable and Implantable Buprenorphine revealed both low uptake and low diversion risk of these products,<sup>i</sup> ASAM respectfully recommends that DEA:

- (1) Increase the number of days a practitioner can administer LAI buprenorphine after receipt of the medication pursuant to authority granted under the SUPPORT Act;
- (2) Clarify that practitioners who are not DATA-waived can administer LAI buprenorphine pursuant to a lawful prescription by a DATA-waived practitioner; and
- (3) Treat pharmacists as a practitioner who may administer long-acting injectable (not implantable) buprenorphine to the extent authorized by state law.

Taken together, this change and these clarifications can help maximize access to LAI buprenorphine products, particularly for patients in rural areas who may lack access to reliable transportation, and those being treated via telemedicine during the COVID-19 Public Health Emergency, whose prescribing practitioners may be unavailable to administer the medication.

If you have any questions or concerns, please contact Susan Awad, Director, Public Policy and Regulatory Affairs at [sawad@asam.org](mailto:sawad@asam.org) or 301-547-4106.

Sincerely,

A handwritten signature in blue ink that reads "Paul H Earley M.D." The signature is written in a cursive, slightly slanted style.

Paul Earley, MD, DFASAM  
President, American Society of Addiction Medicine

---

<sup>i</sup> *Opioid Use Disorder: Treatment with Injectable and Implantable Buprenorphine*, GAO (Aug. 2020), <https://www.gao.gov/assets/710/708581.pdf>